Tyto Care nets CE mark for digital, at-home doctor’s exams

Tyto Care
Tyto Care's consumer-focused home exam devices. (Tyto Care)

Telehealth developer Tyto Care has received a CE mark for its remote medical examination system.

The platform includes a modular, hand-held digital stethoscope and otoscope for checking the heart, lungs, ears, nose and throat, including guidance for performing the steps at home. Video from the exam can be streamed live to a clinician or recorded before a scheduled session for diagnosis.

The company said its European roll out will take place as soon as possible, through partnerships with other telehealth companies, health systems and insurance providers. Tyto received an FDA clearance for its digital stethoscope in 2016.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Receiving CE Mark approval is an important milestone for Tyto Care, and a major step in our continued strategic expansion into Europe and other new markets,” said Dedi Gilad, Tyto’s co-founder and CEO.

“European doctors are struggling to keep up with the increasing medical demand of an aging population and the rise of chronic illnesses,” Gilad added, describing Tyto’s ability to circumvent barriers to care such as transportation and time.

RELATED: Tyto bags $25M to grow U.S. telehealth sales, target China

The Israeli company also has its eyes on expanding to China. In January, Tyto raised $25 million led by the Chinese insurance company Ping An and its Global Voyager Fund, alongside a strategic relationship between the two companies aimed at bringing the telehealth devices to the country.

Other financial backers included Cambia Health Solutions, Walgreens, OrbiMed, Fosun Pharma and LionBird. Tyto thinks telehealth can extend the reach of specialists to patients’ homes and possibly recover revenue lost to emergency care by offering a more convenient option.

Suggested Articles

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. 

Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.